Biogen (BIIB) Long-Term Deferred Tax (2017 - 2026)

Biogen's Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $238.2 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 22.54% year-over-year to $238.2 million; the TTM figure through Mar 2026 stood at $238.2 million (down 22.54% YoY), while the FY2025 annual figure was $292.5 million, down 9.78% from the prior year.
• Long-Term Deferred Tax was $238.2 million for Q1 2026 at Biogen, down from $292.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $1.3 billion in Q1 2022 to a low of $238.2 million in Q1 2026.
• Historically, Long-Term Deferred Tax has averaged $819.5 million across 5 years, with a median of $928.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax rose 0.19% in 2022, then tumbled 67.75% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.2 billion in 2022, then retreated by 24.28% to $928.6 million in 2023, then slumped by 65.09% to $324.2 million in 2024, then declined by 9.78% to $292.5 million in 2025, then fell by 18.56% to $238.2 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $238.2 million (Q1 2026), $292.5 million (Q4 2025), and $312.4 million (Q3 2025), per Business Quant data.